International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
J Hillengass, S Usmani, SV Rajkumar… - The lancet …, 2019 - thelancet.com
Recent advances in the treatment of multiple myeloma have increased the need for accurate
diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the …
diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the …
Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and
durable responses in multiple myeloma. However, relapse following therapy is frequently …
durable responses in multiple myeloma. However, relapse following therapy is frequently …
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
MC Da Vià, O Dietrich, M Truger, P Arampatzi, J Duell… - Nature medicine, 2021 - nature.com
B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker
for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a …
for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a …
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …
The multiple myelomas—current concepts in cytogenetic classification and therapy
SK Kumar, SV Rajkumar - Nature reviews Clinical oncology, 2018 - nature.com
Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …
malignancies and predominantly affects older individuals (with a median age at diagnosis of …
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
The multiple myeloma (MM) genome is heterogeneous and evolves through preclinical and
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
Extramedullary multiple myeloma
Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma,
characterized by the ability of a subclone to thrive and grow independent of the bone …
characterized by the ability of a subclone to thrive and grow independent of the bone …